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Metformin: a multitasking medication  
Most current guidelines and algorithms for the treatment of hyperglycaemia in type 2 diabetes 
suggest metformin as first-choice oral antidiabetic therapy. They point to its antihyperglycaemic efficacy with 
low risk of frank hypoglycaemia, lack of weight gain, and ability to counter insulin resistance without raising 
insulin levels. Independent of glycaemic control there are several potentially beneficial effects on cardiovascular 
risk factors, and evidence of improved cardiovascular outcomes. Additionally, metformin is conveniently 
combined with any other antidiabetic drug, and there are no significant interactions with the battery of lipid-
lowering, antihypertensive and anticoagulant therapies commonly required by type 2 diabetic patients. 
Monitoring commitments are not arduous, and cost is comparatively low. 
 Of course there are tolerability issues, and important contra-indications that must be respected for metformin, 
but with 50 years of clinical use to reflect upon, the verdict is overwhelmingly positive. Yet 30 years ago 
biguanides stood in the dock, their safety criticised and their future bleak. High rates of lactic acidosis sealed the 
withdrawal of phenformin in most countries at the end of the 1970s, soon followed by the disappearance of 
another biguanide, buformin. Accusing fingers pointed at respiratory chain disruption and impaired oxidative 
metabolism with phenformin. Ironically, shortly after phenformin was withdrawn, evidence emerged that a 
genetic variation in the ability to metabolise phenformin affects about 9% of the population, explaining an 
accumulation of the drug in such individuals and their susceptibility to lactic acidosis. But the era of 
pharmacogenomics had still to dawn. 
 Metformin survived, just. It is not metabolised (or hardly so) in man, but it can accumulate if renal impairment 
goes unrecognised. Raised concentrations of metformin may interfere with oxidative metabolism, but much less 
so than with phenformin, and it is well appreciated that the detrimental effects of excess lactate are considerably 
greater in hypoxaemic states. However, metformin-associated lactic acidosis is rare (with an incidence of less 
than 0.1 and probably about 0.03 cases per 1,000 patient-years of treatment), and confidence in this agent has 
reached an all-time high. The benefit:risk balance of metformin has encouraged some commentators to question 
whether the constraints on its usage might be relaxed. But one reason for the continued popularity of the drug 
may be its judicious use, and continued insistence that all precautions continue to be heeded. 
 Metformin exerts a variety of cellular actions in different tissues at different drug concentrations and in 
different metabolic states. These actions are individually modest but collectively sufficient to confer the efficacy 
and breadth of therapeutic effects against diabetes and its vascular complications. The diversity of cellular 
actions may yet extend the medicinal value of metformin, as evidence emerges for helpful effects in the 
treatment of other insulin-resistant states such as polycystic ovarian syndrome (PCOS), nonalcoholic fatty liver 
disease (NAFLD) and the metabolic disturbances that accompany human immunodeficiency virus (HIV). Most 
recently, preliminary reports have raised the possibility that metformin could have some anti-tumour effects. 
The field of therapeutics is strewn with descriptors such as panacea, pleiotropic and holistic, so why not 
multitasking for metformin? 
 
